News Sanofi $750m acquisition gives it edge in flu vacccine marke... Biotech's Flublok is only FDA-approved cell-based flu jab
News Sanofi's bispecific lunsekimig has mixed readouts in phase 2 Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
